161 related articles for article (PubMed ID: 33381933)
1. Comparison of Different Types of Oral Adsorbent Therapy in Patients with Chronic Kidney Disease: A Multicenter, Randomized, Phase IV Clinical Trial.
Kee YK; Han SY; Kang DH; Noh JW; Jeong KH; Kim GH; Kim YW; Kim BS
Yonsei Med J; 2021 Jan; 62(1):41-49. PubMed ID: 33381933
[TBL] [Abstract][Full Text] [Related]
2. Review of the efficacy of AST-120 (KREMEZIN
Asai M; Kumakura S; Kikuchi M
Ren Fail; 2019 Nov; 41(1):47-56. PubMed ID: 30732506
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Shimizu M; Kikuchi M; Shobu Y
Clin Exp Nephrol; 2018 Apr; 22(2):299-308. PubMed ID: 28741050
[TBL] [Abstract][Full Text] [Related]
4. New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study.
Kim SH; Jhee JH; Choi HY; Lee SH; Shin SK; Lee SY; Yang DH; Yi JH; Han SW; Jo YI; Park HC
BMC Nephrol; 2020 Jul; 21(1):317. PubMed ID: 32736531
[TBL] [Abstract][Full Text] [Related]
5. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Arita K; Kato A; Shimizu M
J Am Soc Nephrol; 2015 Jul; 26(7):1732-46. PubMed ID: 25349205
[TBL] [Abstract][Full Text] [Related]
6. The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Shimizu M; Shobu Y; Kikuchi M
BMC Nephrol; 2016 Sep; 17(1):141. PubMed ID: 27716149
[TBL] [Abstract][Full Text] [Related]
7. Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: a randomized crossover study.
Wu IW; Hsu KH; Sun CY; Tsai CJ; Wu MS; Lee CC
Nephrol Dial Transplant; 2014 Sep; 29(9):1719-27. PubMed ID: 24714415
[TBL] [Abstract][Full Text] [Related]
8. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
[TBL] [Abstract][Full Text] [Related]
9. Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
Yamaguchi J; Tanaka T; Inagi R
Nephron; 2017; 135(3):201-206. PubMed ID: 27960172
[TBL] [Abstract][Full Text] [Related]
10. Oral Charcoal Adsorbents Attenuate Neointima Formation of Arteriovenous Fistulas.
Shih YC; Wu CC; Wang SC; Liou JY; Huang PH; Tarng DC
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32276394
[TBL] [Abstract][Full Text] [Related]
11. Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.
Liu WC; Tomino Y; Lu KC
Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30208594
[TBL] [Abstract][Full Text] [Related]
12. Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120.
Six I; Gross P; Rémond MC; Chillon JM; Poirot S; Drueke TB; Massy ZA
Atherosclerosis; 2015 Nov; 243(1):248-56. PubMed ID: 26408929
[TBL] [Abstract][Full Text] [Related]
13. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.
Akizawa T; Asano Y; Morita S; Wakita T; Onishi Y; Fukuhara S; Gejyo F; Matsuo S; Yorioka N; Kurokawa K;
Am J Kidney Dis; 2009 Sep; 54(3):459-67. PubMed ID: 19615804
[TBL] [Abstract][Full Text] [Related]
14. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease.
Yorioka N; Kiribayashi K; Naito T; Ogata S; Yokoyama Y; Kyuden Y; Ogawa T; Wada K; Hayashi K; Hirabayashi A
J Nephrol; 2008; 21(2):213-20. PubMed ID: 18446716
[TBL] [Abstract][Full Text] [Related]
15. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients.
Lee CT; Hsu CY; Tain YL; Ng HY; Cheng BC; Yang CC; Wu CH; Chiou TT; Lee YT; Liao SC
Blood Purif; 2014; 37(1):76-83. PubMed ID: 24576840
[TBL] [Abstract][Full Text] [Related]
16. The role of carbon adsorbent in the conservative management of chronic kidney disease.
Niwa T
Panminerva Med; 2017 Jun; 59(2):139-148. PubMed ID: 27990791
[TBL] [Abstract][Full Text] [Related]
17. Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease.
Marier JF; Lee J; Kambhampati SR; Galitz L; Vargas R; Moberly J; Salazar DE
Am J Nephrol; 2006; 26(2):136-41. PubMed ID: 16549905
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD.
Sakaguchi Y; Hamano T; Obi Y; Monden C; Oka T; Yamaguchi S; Matsui I; Hashimoto N; Matsumoto A; Shimada K; Takabatake Y; Takahashi A; Kaimori JY; Moriyama T; Yamamoto R; Horio M; Yamamoto K; Sugimoto K; Rakugi H; Isaka Y
J Am Soc Nephrol; 2019 Jun; 30(6):1073-1085. PubMed ID: 31036759
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction.
Cha RH; Kang SW; Park CW; Cha DR; Na KY; Kim SG; Yoon SA; Han SY; Chang JH; Park SK; Lim CS; Kim YS
Clin J Am Soc Nephrol; 2016 Apr; 11(4):559-67. PubMed ID: 26912554
[TBL] [Abstract][Full Text] [Related]
20. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure.
Iida S; Kohno K; Yoshimura J; Ueda S; Usui M; Miyazaki H; Nishida H; Tamaki K; Okuda S
Clin Exp Nephrol; 2006 Dec; 10(4):262-7. PubMed ID: 17186330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
